Although several recent studies have confirmed that angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) can reduce DN proteinuria and delay disease progression (8, 9), these have been shown to be ineffective in DN patients with normal blood pressure (10). The gene discussed is ACE; the disease is liver dysplastic nodule.